Not ready to purchase?

Stay in touch about special discounts, nutrition tips and additional education.

Scientific research is our foundation

Scientific Discoveries

Breakthroughs are put to the test with clinical trials

Human Advancement

Through rigorous trial protocols, our knowledge grows

Groundbreaking Innovation

Results help us create effective products that improve your health

Participate in breakthrough research

Clinical trials are integral to developing new approaches to medicine. Through collaboration with leading academic research institutions, top investigators, and passionate human beings all over the world, we grow our understanding of the microbiome and unravel its connection to your health — together.

Explore our studies

Clinical Trials

All Trials

PRO-PLATINUM: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Probiotic Intervention on the Gut and Vaginal Microbiome of Ovarian Cancer Patients Undergoing Treatment with Platinum Chemotherapy

Duration:6 chemotherapy cycles (about 6 months)

Eligibility:Ovarian cancer patients undergoing chemotherapy

Status:Now enrolling

Conducted by:The Ohio State University Wexner Medical Center

Enroll now

Principal Investigator:Laura Chambers, DO

Design:Double-blind, placebo-controlled study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT07144826

The study:This study investigates the efficacy of a probiotic intervention in altering the gut microbiome of 124 women with advanced (stage II, III or IV) or recurrent platinum-sensitive ovarian cancer who are receiving platinum-based chemotherapy (cisplatin or carboplatin-containing regimens).

Goal:To evaluate changes in gut microbiome composition in ovarian cancer patients randomized to a probiotic intervention versus placebo during platinum chemotherapy.

Show less

Pendulum Metabolic Daily

Fecal Microbiota Transplantation for Auto-Brewery Syndrome

Duration:9 months

Eligibility:Adults with diagnosis of Auto-Brewery Syndrome (ABS) and documented ABS symptoms for at least one year, including supervised ethanol testing or a positive glucose challenge test in a supervised setting.

Status:Now enrolling

Conducted by:Massachusetts General Hospital

Enroll now

Principal Investigator:Elizabeth L. Hohmann, MD

Estimated enrollment:8 adults

Design:Open-label pilot study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT06083142

The study:This Phase 1 clinical trial, funded by the National Institute of Health (NIH), will explore the safety and tolerability of Fecal Microbiota Transplantation (FMT) in 8 patients with ABS.

Goal:The goal of this study is to assess the safety and feasibility of antibiotic “clean out” pretreatment, microbial restoration via capsule FMT, and daily administration of potato starch and Pendulum Metabolic Daily for 9 months to manage Auto-Brewery Syndrome. Additionally, the goal will be to understand how the treatment affects breathalyzer blood alcohol levels and whether the gut bacteria in patients with ABS can durably be impacted.

Show less

Pendulum Glucose Control

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Duration:18 months (including baseline, intervention, and follow-up)

Eligibility:Women with early-stage hormone receptor-positive breast cancer initiating aromatase inhibitor therapy

Status:Now enrolling

Conducted by:Mayo Clinic in Florida

Enroll now

Estimated enrollment:30 women. Cohort 1: 20 Postmenopausal women & Cohort 2: 10 Premenopausal or perimenopausal women on ovarian function suppression

Design:Phase II, open-label, interventional study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT07044310

The study:This investigator-initiated clinical trial evaluates the effects of Pendulum Glucose Control in preventing bone loss among women with early-stage hormone receptor-positive breast cancer starting aromatase inhibitor therapy. Aromatase inhibitors are commonly used in breast cancer treatment, but are known to adversely affect bone health, body weight, blood glucose levels, and waist circumference. Participants will receive Pendulum Glucose Control for 12 months, beginning three months after initiating aromatase inhibitor therapy. Assessments will include blood samples, bone mineral density (BMD) testing, and patient-reported outcomes. Follow-up will continue for 3 months after treatment concludes.

Goal:To assess the efficacy of Pendulum Glucose Control in mitigating aromatase inhibitor-associated bone loss, as measured by changes in C-terminal telopeptide of type 1 collagen (CTx) levels and bone mineral density. Secondary goals include evaluating safety, metabolic biomarkers, changes in body weight and waist circumference, cytokine profiles, gut microbiome associations, and aromatase inhibitor-related musculoskeletal symptoms.

Show less

A Two-Phase Study on the Safety and Tolerance of a Novel Probiotic in Healthy Adults: Open-Label and Double-Blind, Placebo-Controlled Study

Duration:2 months

Eligibility:Healthy adults, aged between 18-65 years old

Status:Active, Fully Enrolled

Conducted by:Pendulum Therapeutics

Estimated enrollment:Phase 1: 30 people | Phase 2: 60 people

Design:Phase 1: Open-Label Study | Phase 2: Randomised Double-Blind, Placebo-Controlled Study

Date of completion:Estimated 2025

The study:Pendulum Therapeutics is conducting a Two-Phase Study on the Safety and Tolerance of a Pendulum Probiotic. The first phase will look at two different doses of the probiotic and it’s impact on food cravings and GLP-1 plasma levels. Results from the open-label phase one study will guide dose information for the Phase Two double blinded, placebo controlled study.

Goal:Evaluate the impacts of daily consumption of Pendulum Probiotic on measures of food cravings and plasma GLP-1 levels.

Show less

Supplementation with a next-generation synbiotic in individuals who are overweight or with obesity: a triple-blinded, randomized, controlled clinical trial

Duration:3 months

Eligibility:Adults ages 18-50, BMI: 25-40 without a diabetes diagnosis

Status:Completed

Conducted by:Texas Christian University

Study details

Estimated enrollment:60 participants

Design:Triple-blinded, randomized, placebo-controlled

Date of completion:Estimated April 2025

ClinicalTrials.gov Identifier:NCT06213480

The study:Texas Christian University is recruiting participants ages 18-50 that have a BMI between 25-40 and do not have diabetes diagnosis to join a 3-month study of Pendulum Probiotic and measures of body composition, metabolic health, mood and eating behavior.

Goal:Evaluate impacts of daily consumption of Pendulum Glucose Control on measures of body composition, metabolic health, mood, and food behavior.

Show less

A Randomized, Double-Blind, Placebo-Controlled Study of Probiotics As Adjuvant Therapy for Bipolar Depression: A Proof-of-Concept Trial

Duration:12 weeks

Eligibility:Adults with a medical diagnosis of bipolar disease (type I or II) receiving approved treatments for bipolar depression for at least 4 weeks

Status:Completed

Conducted by:University of São Paulo, Brazil (FMSUP)

Study details

Estimated enrollment:84 participants

Design:Randomized, double-blind, placebo-controlled trial

Date of completion:January 2025

ClinicalTrials.gov Identifier:NCT06213480

The study:University of São Paulo Bipolar Research Program is recruiting adults with bipolar (type I & II) presenting with subclinical depressive symptoms or a major depressive episode to participate in an outpatient randomized, double-blind, placebo-controlled trial that will last 12 weeks.

Goal:In a proof-of-concept study, evaluate the antidepressant efficacy of adjunctive administration of probiotics in participants with bipolar depression and evaluate potential inflammatory and metabolic markers associated with response to treatment.

Show less

Akkermanisa and akkermansia 500 pro

Detection of Akkermansia muciniphila utilizing serial longitudinal samples with the BiomeSense GutLab^TM: an open-label proof of concept study

Duration:4 months

Eligibility:Adults, ages 18-75, and in general good health,
local to the San Francisco Bay Area or Chicago, IL

Status:Completed

Conducted by:Pendulum Therapeutics, BiomeSense

Press release

Estimated enrollment:10 participants + household controls

Design:Open-label

Date of completion:November 2024

The study:Pendulum Therapeutics in partnership with BiomeSense are conducting a 4-month study of Pendulum Akkermansia measuring the serial longitudinal detection of the probiotic strain using BiomeSense GutLab^TM technology.

Goal:Evaluate serial longitudinal detection of Akkermansia and Akkermansia 500 PRO in stool samples of healthy individuals over an 8-week supplementation period.

Show less

OsteoPreP Study: Evaluating how Pendulum probiotics can support bone health in early postmenopausal women

Duration:12 months

Eligibility:Postmenopausal women, 40-65 years

Status:Completed

Conducted by:Australian Catholic University, Pendulum Therapeutics

Study details

Estimated enrollment:160 participants

Design:Double-blinded, randomized, placebo controlled

Date of completion:Estimated May 2025

ClinicalTrials.gov Identifier:NCT05348694

The study:Studies indicate a potential link between the gut microbiome and bone health. Australian Catholic University is recruiting female participants within 1 to 4 years of their final menses to join this 12-month study of Pendulum Probiotic and bone health.

Goal:To measure the impacts of long-term probiotic supplementation in early postmenopausal women on bone, muscle and metabolic health.

Press Release: Researchers look at whether probiotics can slow osteoporosis in early menopause

Show less

PENDULUM GLUCOSE CONTROL

Evaluating the safety and metabolic effects of Pendulum probiotics on glucose control associated with Type 2 diabetes

Duration:3 months

Eligibility:Type 2 diabetes, metformin, 18-75 years

Status:Completed

Conducted by:Pendulum Therapeutics

Estimated enrollment:76 participants

Design:Double-blinded, randomized, placebo controlled

Date of completion:September 2018

ClinicalTrials.gov Identifier:NCT03893422

The study:12-week double-blind, randomized placebo-controlled, proof of concept study, evaluating the safety and metabolic effects of Pendulum probiotics in the overall dietary management of Type 2 diabetes.

Goal:To evaluate the safety and metabolic effects of Pendulum probiotics on glucose control associated with Type 2 diabetes.

Results:Study participants that were administered Pendulum Glucose Control had statistically and clinically significant improvements. In individuals with Type 2 diabetes on Metformin, A1c levels were reduced by 0.6% and postprandial glucose spikes (Area Under the Curve or AUC) were reduced by 33%, as compared to placebo. Pendulum Glucose Control was safe and well-tolerated by study participants.

Press Release: First-Ever Medical Probiotic That Provides The Dietary Management Of A1C And Blood Glucose Levels

Scientific Publication: BMJ Open Diabetes Research & Care

Show less

PENDULUM GLUCOSE CONTROL

Proof of concept study, evaluating Pendulum probiotics use in conjunction with continuous glucose monitoring smartphone app measurements

Duration:6 weeks

Eligibility:18-75 years

Status:Completed

Conducted by:Pendulum Therapeutics

Estimated enrollment:6 participants

Design:Double-blinded, randomized, placebo controlled, cross-over proof of concept study

Date of completion:June 2018

ClinicalTrials.gov Identifier:NCT04424888

The study:Self-administered meal-tolerance tests conducted to assess the impact of Pendulum Glucose Control on glucose levels through continuous glucose monitoring smart phone app measurements.

Goal:Proof-of-concept study to investigate the potential of collecting robust, real-time clinical study measures of glucose levels without clinic visits.

Results:Participants reported general satisfaction with sensor management, Pendulum Glucose Control, and the smartphone app. Despite a lack of sufficient power to achieve statistical significance, meaningful changes in the postprandial glucose response in real-world settings were detected, meriting larger studies in the future.

Press Release: Continuous Glucose Monitors Could Modernize Clinical Trials with Remote Data Collection

Scientific Publication: JMIR Formative Research

Show less

PRO-PLATINUM: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Probiotic Intervention on the Gut and Vaginal Microbiome of Ovarian Cancer Patients Undergoing Treatment with Platinum Chemotherapy

Duration:6 chemotherapy cycles (about 6 months)

Eligibility:Ovarian cancer patients undergoing chemotherapy

Status:Now enrolling

Conducted by:The Ohio State University Wexner Medical Center

Enroll now

Principal Investigator:Laura Chambers, DO

Design:Double-blind, placebo-controlled study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT07144826

Goal:To evaluate changes in gut microbiome composition in ovarian cancer patients randomized to a probiotic intervention versus placebo during platinum chemotherapy.

Show less

Pendulum Metabolic Daily

Fecal Microbiota Transplantation for Auto-Brewery Syndrome

Duration:9 months

Status:Now enrolling

Conducted by:Massachusetts General Hospital

Enroll now

Principal Investigator:Elizabeth L. Hohmann, MD

Estimated enrollment:8 adults

Design:Open-label pilot study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT06083142

The study:This Phase 1 clinical trial, funded by the National Institute of Health (NIH), will explore the safety and tolerability of Fecal Microbiota Transplantation (FMT) in 8 patients with ABS.

Show less

Pendulum Glucose Control

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Duration:18 months (including baseline, intervention, and follow-up)

Eligibility:Women with early-stage hormone receptor-positive breast cancer initiating aromatase inhibitor therapy

Status:Now enrolling

Conducted by:Mayo Clinic in Florida

Enroll now

Estimated enrollment:30 women. Cohort 1: 20 Postmenopausal women & Cohort 2: 10 Premenopausal or perimenopausal women on ovarian function suppression

Design:Phase II, open-label, interventional study

Date of completion:Estimated 2026

ClinicalTrials.gov Identifier:NCT07044310

Show less

Become a microbiome pioneer

If you're interested in participating in our research, sign up and we'll send you information about upcoming programs and eligibility requirements. You do not need to be a Pendulum customer to be considered.

Learn more